Drug development

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Dispense and Imaging Assays – Moving towards a more balanced use of both fluorescence and flash luminescent readouts

Dispense and Imaging Assays - Moving towards a more balanced use of both fluorescence and flash luminescent readouts By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec's recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests… Read More

#Archive

#ADME / Tox #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #RNA #Screening #Toxicology

The Importance of Liquid Handling Quality Assurance in Drug Discovery

The Importance of Liquid Handling Quality Assurance in Drug Discovery By Dr Nathaniel G Hentz The tug-of-war between quality and productivity is an issue facing all drug discovery companies, competing in a fierce race to bring breakthrough drugs to market before the competition.   With the advance of laboratory automation… Read More

#Archive

#Animal models #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Immunology #Lead discovery #Oncology #Regulatory #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Advances in Antibody Therapy – A promising new approach to how we treat cancer

Advances in Antibody Therapy - A promising new approach to how we treat cancer By Dr Patrick A Baeuerle Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited. Currently, four conventional antibody products dominate the oncology… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Pharmokinetics #Preclinical #RNA

Lean Six Sigma – Its application to drug discovery

Lean Six Sigma - Its application to drug discovery By Clare Hammond and Charles J O'Donnell In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #In Silico Biology #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Progress in Systems-Based Analysis of Cellular Signalling

Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Needs and challenges in High Throughput Screening

Needs and challenges in High Throughput Screening By William Downey, Dr Helen Nicely and Dr Lynne Sopchak High throughput screening (HTS) groups face similar challenges as the pharmaceutical and biotechnology industry as a whole faces. HTS groups are looking for ways to improve effectiveness in lead discovery, increase their productivity… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Microfluidics #PCR #Pharmokinetics #RNA #Screening #Sequencing #Stem cells

Microplate Mixing – Bioassay panacea or of unproven distraction?

Microplate Mixing - Bioassay panacea or of unproven distraction? By Dr John Comley Despite general awareness of the significance of microplate mixing, it is still a relatively low priority in most laboratories. Microplate mixing has largely been ignored as a serious problem, although potentially it could undermine the generation of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #High throughput screening #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #Target validation #Toxicology

Human ES Cell Derived Functional Cells as Tools in Drug Discovery

Human ES Cell Derived Functional Cells as Tools in Drug Discovery By Dr Petter Bjorquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Organic chemistry #Pathology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Perspectives for ADMET Integration in the Discovery Process

Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More

#Archive

#Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #RNA #Screening #System biology #Systems biology

Compound Storage Evolution: Unlocking the right combination

Compound Storage Evolution: Unlocking the right combination By Husam Fayez, Dr John Morin and Dr Jeff Paslay Delivering the correct compound, at the right concentration, to the correct place, at the expected time across different facilities, should be the aim of all liquid sample management teams. This article discusses how… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Oncology #Regulatory #RNA #Toxicology

The Role of Thorough QT Testing in Managing Drug Development

The Role of Thorough QT Testing in Managing Drug Development By Dr William S. Wheeler With few exceptions, all compounds being submitted to the Food and Drug Administration (FDA) for approval in the United States will require an assessment of QT prolongation, either by a standard Thorough QT/QTc study, or… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Pathology #Pharmokinetics #RNA

Opportunities in Gastroenterology

Opportunities in Gastroenterology By Dirk Reyn Despite being one of the world's largest therapeutic areas and presenting huge burdens to healthcare and economies globally, many of the diseases of the gastrointestinal (GI) tract are not well understood and less than optimally treated. This article discusses that, given the large public… Read More

#Archive

#Biomarkers #Business #Cell / tissue culture #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Preclinical #Regulatory #Target validation

Novartis Vaccines – Leading through innovation and technology

Novartis Vaccines - Leading through innovation and technology By Dr Joerg Reinhardt Every year, vaccines save millions of lives by preventing major human diseases, protecting individuals and those close to them, and offering widespread public defence against disease. In 2006, Novartis joined the vaccines market when it acquired Chiron, creating… Read More

#Archive

#Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Sequencing #System biology #Systems biology #Target validation #Toxicology

Next Generation DNA Sequencing Technologies

Next Generation DNA Sequencing Technologies By Dr Bruce E. Taillon and Brendon Hill Human genetics is the foundation of disease as well as the response to pharmaceutical agents. Today, promising drugs are abandoned due to the lack of significant efficacy in broad patient populations. Recently, blockbuster drugs have been removed… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #Sequencing #Stem cells #System biology #Systems biology

21st Century Vaccines – A Development Renaissance

21st Century Vaccines - A Development Renaissance By Dr Jeff Stoddard, Charles Drucker and Dr Nigel Brown Human beings have benefited from vaccines for more than two centuries. From eradicating some of the deadliest diseases to nearly eliminating a host of others, including polio, measles, mumps and tetanus - vaccines… Read More

#Archive

#Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Orphan drugs #PCR #Pharmacology #Regulatory #Screening #Stem cells #System biology #Systems biology

GPCRs – New Strategies for an Old Target Class

William Downey and Dr Shauna Farr-Jones GPCRs are the most studied drug target class and have a proven record as valuable drug targets, with 40-50% of marketed drugs being modulators of GPCR function. Despite the intense effort focused on these targets by the pharmaceutical industry over many years, numerous challenges… Read More

#Archive